Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating two doses of belantamab mafodotin in multiple myeloma patients who previously failed anti-CD38 therapy; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2020-04-28